drug
delafloxacin meglumine
Marketedupdated 5mo agoby Melinta Therapeutics LLC
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jun 19, 2027
251 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (18)
- Jun 2, 2034method-of-use (U-3967)US 12036219
- Mar 14, 2034method-of-use (U-3967)US 12558349
- Feb 27, 2033formulationUS 9493582
- May 1, 2032formulationUS 12138257
- Jun 19, 2031compositionUS 77281434.7y
- Jun 19, 2031compositionUS 77281434.7y
- Dec 28, 2029compositionUS RE466173.2y
- Dec 28, 2029compositionUS RE466173.2y
- Sep 23, 2029compositionUS 88719383.0y
- Sep 23, 2029compositionUS 88719383.0y
- Mar 13, 2029formulationUS 76357732.4y
- Mar 13, 2029formulationUS 84100772.4y
- Mar 13, 2029formulationUS 92000882.4y
- Mar 13, 2029formulationUS 97508222.4y
- Oct 2, 2026formulationUS 8252813
- Oct 2, 2026formulationUS 8252813
- Aug 6, 2026compositionUS 8273892
- Aug 6, 2026compositionUS 8273892
FDA exclusivities (4)
- Jun 19, 2027GAINGAIN Antibiotic (5y)251d
- Jun 19, 2027GAINGAIN Antibiotic (5y)251d
- Jun 19, 2022NCENew Chemical Entity (5y)
- Jun 19, 2022NCENew Chemical Entity (5y)
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 22m ago
Found something off?
comments(0)
5-min edit window · permanent after that